Insider · CIK 0001610384
Remy Luthringer
Files at NERV (Minerva Neurosciences, Inc.). First filing -, latest -.
In brief
Remy Luthringer files SEC Form 4 as CEO and director at NERV (Minerva Neurosciences, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Remy Luthringer has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | NERV Minerva Neurosciences, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +1,690,700 | $0.00 | $0 | 1,690,700 | Jun 5, 2026 |
| Dec 22, 2025 | NERV Minerva Neurosciences, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +2,250,000 | $0.00 | $0 | 2,250,000 | Dec 23, 2025 |
| Dec 5, 2024 | NERV Minerva Neurosciences, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +105,000 | $0.00 | $0 | 105,000 | Dec 6, 2024 |
Questions about Remy Luthringer
Answered from the filings on this page, as of the latest one.
Is Remy Luthringer buying or selling?
Remy Luthringer has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Remy Luthringer's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Remy Luthringer has 0.
Where does Remy Luthringer file Form 4?
Remy Luthringer has filed Form 4 at NERV (Minerva Neurosciences, Inc.) as CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.